Genetically Evaluating the Causal Role of Peripheral Immune Cells in Colorectal Cancer: a Two-sample Mendelian Randomization Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Jun 20

PMID 38902711

Authors

Runze Huang

Xin Jin

Ziting Jiang

Yixiu Wang

Yibin Wu

Lu Wang

Weiping Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Investigating novel therapeutic strategies for colorectal cancer (CRC) is imperative. However, there is limited research on the use of drugs to target peripheral blood immune cells in this context. To address this gap, we performed a two-sample Mendelian randomization (MR) analysis to identify potential therapeutic targets for CRC.

Methods: We applied two-sample MR to identify the causal relationship between peripheral blood immune cells and CRC. GWAS data were obtained from the IEU OPEN GWAS project. Based on the implications from the MR results, we conducted a comprehensive database search and genetic analysis to explore potential underlying mechanisms. We predicted miRNAs for each gene and employed extensive research for potential therapeutic applications.

Results: We have identified causal associations between two peripheral immune cells and colorectal cancer. Activated & resting Treg %CD4 + cell was positively associated with the risks of CRC, while DN (CD4-CD8-) %leukocyte cell exhibited a protective role in tumor progression. NEK7 (NIMA related kinase 7) and LHX9 (LIM homeobox 9) expressed in Treg cells were positively associated with CRC risks and may play a vital role in carcinogenesis.

Conclusions: This study identified causal relationship between peripheral immune cell and CRC. Treg and DN T cells were implicated to own promoting and inhibiting effects on CRC progression respectively. NEK7 and LHX9 in Treg cells were identified as potential biotarget for antitumor therapies.

References

Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H . Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003; 9(12):4404-8. View

Nixon A, Schalper K, Jacobs I, Potluri S, Wang I, Fleener C . Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?. J Immunother Cancer. 2019; 7(1):325. PMC: 6880594. DOI: 10.1186/s40425-019-0799-2. View

Vladimirova V, Mikeska T, Waha A, Soerensen N, Xu J, Reynolds P . Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia. 2009; 11(7):700-11. PMC: 2697356. DOI: 10.1593/neo.09406. View

Fang L, Ly D, Wang S, Lee J, Kang H, Xu H . Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. J Exp Clin Cancer Res. 2019; 38(1):123. PMC: 6413451. DOI: 10.1186/s13046-019-1126-y. View

Tang Y, Xie M, Li K, Li J, Cai Z, Hu B . Prognostic value of peripheral blood natural killer cells in colorectal cancer. BMC Gastroenterol. 2020; 20(1):31. PMC: 7006176. DOI: 10.1186/s12876-020-1177-8. View

Zhang Q, Wang C, Li R, Liu J, Wang J, Wang T . The BAP31/miR-181a-5p/RECK axis promotes angiogenesis in colorectal cancer fibroblast activation. Front Oncol. 2023; 13:1056903. PMC: 9989165. DOI: 10.3389/fonc.2023.1056903. View

Guo W, Sun Y, Liu W, Wu X, Guo L, Cai P . Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy. 2014; 10(6):972-85. PMC: 4091180. DOI: 10.4161/auto.28374. View

Tomeva E, Krammer U, Switzeny O, Haslberger A, Hippe B . Sex-Specific miRNA Differences in Liquid Biopsies from Subjects with Solid Tumors and Healthy Controls. Epigenomes. 2023; 7(1). PMC: 9844450. DOI: 10.3390/epigenomes7010002. View

Cannioto R, Sucheston-Campbell L, Hampras S, Goode E, Knutson K, Ness R . The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. Int J Gynecol Cancer. 2016; 27(1):11-16. PMC: 5177489. DOI: 10.1097/IGC.0000000000000845. View

10.

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

11.

Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke P . Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci Transl Med. 2016; 8(352):352ra110. PMC: 7780242. DOI: 10.1126/scitranslmed.aaf6843. View

12.

Haq T, Richards M, Burgess S, Gallego P, Yeoh S, ORegan L . Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization. Nat Commun. 2015; 6:8771. PMC: 4632185. DOI: 10.1038/ncomms9771. View

13.

Ishida T, Ueda R . CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006; 97(11):1139-46. PMC: 11159356. DOI: 10.1111/j.1349-7006.2006.00307.x. View

14.

Wicherek L, Jozwicki W, Windorbska W, Roszkowski K, Lukaszewska E, Wisniewski M . Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report. Am J Reprod Immunol. 2011; 66(5):444-50. DOI: 10.1111/j.1600-0897.2011.01024.x. View

15.

Santamaria J, Borelli A, Irla M . Regulatory T Cell Heterogeneity in the Thymus: Impact on Their Functional Activities. Front Immunol. 2021; 12:643153. PMC: 7904894. DOI: 10.3389/fimmu.2021.643153. View

16.

Zhou L, Wang Z, Xu X, Wan Y, Qu K, Fan H . Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo. Oncotarget. 2016; 7(14):18620-30. PMC: 4951314. DOI: 10.18632/oncotarget.7620. View

17.

Bates G, Fox S, Han C, Leek R, Garcia J, Harris A . Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34):5373-80. DOI: 10.1200/JCO.2006.05.9584. View

18.

Majeed U, Manochakian R, Zhao Y, Lou Y . Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021; 14(1):108. PMC: 8264982. DOI: 10.1186/s13045-021-01121-2. View

19.

Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft A . CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol. 2009; 144(5):686-95. DOI: 10.1111/j.1365-2141.2008.07530.x. View

20.

Yan Z, Qu J, Li Z, Yi J, Su Y, Lin Q . NEK7 Promotes Pancreatic Cancer Progression And Its Expression Is Correlated With Poor Prognosis. Front Oncol. 2021; 11:705797. PMC: 8290842. DOI: 10.3389/fonc.2021.705797. View